INS and fatty liver disease: Markers significantly correlated with FLI in non-parametric Spearman’s correlation analysis (i.e., HbA1c, HDL-c, ALT, hsCRP and endocan), but not used for FLI calculation, as well as demographic characteristics significantly different between FLI groups (i.e., gender, antihyperglycemic, insulin and antihypertensive therapies) were used in Model to test the independent prediction of endocan for fatty liver disease.